公开(公告)号：US20210101138A1

公开(公告)日：2021-04-08

申请号：US17118796

申请日：2020-12-11

申请人： BOARD OF TRUSTEES OF THE UNIVERSITY OF ARKANSAS

发明人： SUSANNE STRIEGLER

IPC分类号： B01J31/22 ,  C07H3/02 ,  C07H1/00 ,  C07F1/00 ,  C07C215/44 ,  C07C211/36

摘要： Disclosed herein is a class of chiral binuclear metal complexes for stereoselective hydrolysis of saccharides and glycosides, and more particular chiral binuclear transition metal complex catalysts that discriminate epimeric glycosides and α- and β-glycosidic bonds of saccharides in aqueous solutions at near physiological pHs. The chiral binuclear metal complexes include a Schiff-base-type ligand derived from a chiral diamino building block, and a binuclear transition metal core, each which can be varied for selectivity. The metal core is a Lewis-acidic metal ion, such as copper, zinc, lanthanum, iron and nickel. The Schiff-base may be a reduced or non-reduced Schiff-base derived from aliphatic linear, aliphatic cyclic diamino alcohols or aromatic aldehydes. The ligand can be a penta- or heptadentate ligand derived from pyridinecarbaldehydes, benzaldehydes, linear or cyclic diamines or diamino alcohols.

公开(公告)号：US10662141B2

公开(公告)日：2020-05-26

申请号：US16340478

申请日：2017-10-09

申请人： BASF SE

发明人： Armin Lange De Oliveira ,  Ines Lottenburger ,  Christian Bechtold ,  Thomas Heidemann

IPC分类号： C07C209/72 ,  C07C211/36 ,  C07C209/84 ,  C07C209/86

摘要： Process for hydrogenating toluenediamine (TDA) tar containing TDA and high boilers relative to TDA, including the step of contacting the toluenediamine tar with a heterogeneous hydrogenation catalyst comprising at least one metal selected from the group consisting of Ni, Co, Ru, Pd, Pt on at least one catalyst support selected from the group consisting of carbon, TiO2 and ZrO2, and with hydrogen under hydrogenating conditions.

公开(公告)号：US20190241501A1

公开(公告)日：2019-08-08

申请号：US16340478

申请日：2017-10-09

申请人： BASF SE

发明人： Armin LANGE DE OLIVEIRA ,  Ines LOTTENBURGER ,  Christian BECHTOLD ,  Thomas HEIDEMANN

IPC分类号： C07C209/72 ,  C07C211/36

摘要： Process for hydrogenating toluenediamine (TDA) tar containing TDA and high boilers relative to TDA, including the step of contacting the toluenediamine tar with a heterogeneous hydrogenation catalyst comprising at least one metal selected from the group consisting of Ni, Co, Ru, Pd, Pt on at least one catalyst support selected from the group consisting of carbon, TiO2 and ZrO2, and with hydrogen under hydrogenating conditions.

公开(公告)号：US10196338B2

公开(公告)日：2019-02-05

申请号：US15313474

申请日：2015-05-26

申请人： University College Dublin

发明人： Declan Gilheany ,  Bartosz Bieszczad

IPC分类号： C07C45/69 ,  C07C29/40 ,  C07D311/76 ,  C07D235/12 ,  C07C211/36 ,  C07C211/53 ,  C07C215/50 ,  C07C215/64 ,  C07C41/30

摘要： Processes for stereoselective preparation of a chiral alcohol or a chiral amine are described. The processes include reacting a first prochiral reactant selected from the group consisting of a ketone, an aldehyde, and an imine, with a second reactant that includes a Grignard reagent, in the presence of a chiral trans-diamine of formula (1) as defined herein:

公开(公告)号：US10016436B2

公开(公告)日：2018-07-10

申请号：US15611108

申请日：2017-06-01

申请人： Celgene Corporation

发明人： Stacie S. Canan ,  Natalie Anne Hawryluk

IPC分类号： A61K31/52 ,  C07D473/32 ,  C07D211/36 ,  C07D231/02 ,  G01N33/569 ,  C07C13/06 ,  C07C217/02 ,  C07C211/36

摘要： Provided herein are Purine Comounds of Formula (I) or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of a Purine Compound, and methods for treating or preventing malaria comprising the administration of an effective amount of a Purine Compound.

公开(公告)号：US10010555B2

公开(公告)日：2018-07-03

申请号：US15611061

申请日：2017-06-01

申请人： Celgene Corporation

发明人： Stacie S. Canan ,  Natalie Anne Hawryluk ,  Michael John Witty

IPC分类号： A61K31/52 ,  C07D473/32 ,  C07D413/02 ,  C07C211/57 ,  C07C211/36 ,  C07C13/10 ,  C07C13/06 ,  C07C217/02 ,  G01N33/569

摘要： Provided herein are Aminopurine compounds of Formula I: or pharmaceutically acceptable salts, tautomers, isotopologues, or stereoisomers thereof, wherein R1, R2, and R3 are as defined herein, compositions comprising an effective amount of an Aminopurine Compound, and methods for treating or preventing animal and human protozoal infections.

公开(公告)号：US09328058B2

公开(公告)日：2016-05-03

申请号：US13054945

申请日：2009-07-17

申请人： Lars Wittenbecher ,  Michael Henningsen ,  Gregor Daun ,  Dieter Flick ,  Joerg-Peter Geisler ,  Juergen Schillgalies ,  Erhard Jacobi

发明人： Lars Wittenbecher ,  Michael Henningsen ,  Gregor Daun ,  Dieter Flick ,  Joerg-Peter Geisler ,  Juergen Schillgalies ,  Erhard Jacobi

IPC分类号： C09K3/00 ,  C08L63/00 ,  C08G59/14 ,  C07C211/36 ,  C07C279/04 ,  C08G59/40 ,  C08G59/50 ,  C09J163/00

CPC分类号： C07C211/36 ,  C07C279/04 ,  C08G59/4021 ,  C08G59/50 ,  C09J163/00

摘要： The present invention provides a mixture comprising at least three hardener components a1), a2), and b), the ratio of hardener component a1) to a2) being in the range from 0.1 to 10:1, and hardener component b) being present at 5% to 55% by weight, based on the mixture, a process for preparing this mixture, the use of the mixture of the invention for curing epoxy resins, the use of the mixture of the invention with epoxy resins as adhesives, and an epoxy resin cured with the mixture of the invention.

摘要翻译： 本发明提供包含至少三种硬化剂组分a1），a2）和b）的混合物，硬化剂组分a1）至a2）的比例为0.1-10:1，并且硬化剂组分b）存在 基于该混合物的5重量％至55重量％，制备该混合物的方法，使用本发明混合物固化环氧树脂，本发明混合物与环氧树脂作为粘合剂的用途，以及 用本发明的混合物固化的环氧树脂。

公开(公告)号：US09283196B1

公开(公告)日：2016-03-15

申请号：US14800823

申请日：2015-07-16

申请人： Dennis Michael Godek ,  Harry Ralph Howard

发明人： Dennis Michael Godek ,  Harry Ralph Howard

IPC分类号： A61K31/426 ,  A61K31/41 ,  A61K31/4196 ,  A61K31/417 ,  A61K31/131 ,  A61K31/138 ,  A61K31/135 ,  A61K31/341 ,  A61K31/4409 ,  A61K31/4406 ,  A61K31/40 ,  A61K31/5375 ,  A61K31/495 ,  C07D233/64 ,  C07D249/08 ,  C07D257/04 ,  C07D277/28 ,  C07D277/64 ,  C07C211/37 ,  C07C211/36 ,  C07C217/74

CPC分类号： A61K31/135 ,  A61K31/341 ,  A61K31/40 ,  A61K31/417 ,  A61K31/4406 ,  A61K31/4409 ,  A61K31/495 ,  A61K31/5375 ,  C07D207/09 ,  C07D213/38 ,  C07D233/61 ,  C07D233/64 ,  C07D235/14 ,  C07D249/08 ,  C07D257/04 ,  C07D277/28 ,  C07D277/64 ,  C07D295/13 ,  C07D307/14

摘要： The invention is directed to the use of a compound of formula I as defined herein, a pharmaceutically acceptable salt thereof; or a pharmaceutical composition containing a compound of formula I, in treating a mammal, including a human, for a psychiatric disorder or condition selected from the group consisting of depression, mood disorders, anxiety, schizophrenia, bipolar disorder (also referred to as manic-depressive disorder), addiction, cognitive impairment, Parkinson's and Alzheimer's diseases.

摘要翻译： 本发明涉及本文定义的式I化合物及其药学上可接受的盐的用途; 或含有式I化合物的药物组合物在治疗哺乳动物（包括人）中用于选自以下的精神障碍或病症：抑郁症，情绪障碍，焦虑，精神分裂症，双相情感障碍（也称为躁狂症） 抑郁障碍），成瘾，认知障碍，帕金森病和阿尔茨海默病。

公开(公告)号：US07868204B2

公开(公告)日：2011-01-11

申请号：US11091025

申请日：2005-03-25

申请人： Daniel Delorme ,  Soon Hyung Woo ,  Arkadii Vaisburg ,  Oscar Moradei ,  Silvana Leit ,  Stephane Raeppel ,  Sylvie Frechette ,  Giliane Bouchain

发明人： Daniel Delorme ,  Soon Hyung Woo ,  Arkadii Vaisburg ,  Oscar Moradei ,  Silvana Leit ,  Stephane Raeppel ,  Sylvie Frechette ,  Giliane Bouchain

IPC分类号： C07C211/51 ,  C07C211/36 ,  C07D295/02 ,  C07D263/02 ,  C07D273/02 ,  C07D317/06 ,  C07D317/48 ,  C07D319/18 ,  A61K31/136 ,  A61K31/166 ,  A61K31/34 ,  A61K31/357 ,  A61P35/00

CPC分类号： A61K31/4015 ,  A61K31/445 ,  A61K31/495 ,  A61K31/513 ,  A61K31/53 ,  A61K31/537 ,  C07C233/44 ,  C07C233/80 ,  C07C235/38 ,  C07C235/42 ,  C07C235/56 ,  C07C235/84 ,  C07C237/20 ,  C07C237/22 ,  C07C237/40 ,  C07C237/42 ,  C07C255/58 ,  C07C255/59 ,  C07C275/34 ,  C07C275/36 ,  C07C311/42 ,  C07C323/32 ,  C07C323/36 ,  C07C323/44 ,  C07C323/60 ,  C07C381/00 ,  C07D213/30 ,  C07D213/74 ,  C07D231/12 ,  C07D233/56 ,  C07D233/64 ,  C07D239/91 ,  C07D249/08 ,  C07D251/18 ,  C07D251/52 ,  C07D251/54 ,  C07D263/14 ,  C07D263/24 ,  C07D265/36 ,  C07D271/06 ,  C07D277/42 ,  C07D277/74 ,  C07D277/82 ,  C07D295/155 ,  C07D307/12 ,  C07D307/28 ,  C07D311/56 ,  C07D311/58 ,  C07D333/36 ,  C07D333/38 ,  C07D401/12 ,  C07D403/04 ,  C07D409/12 ,  C07D473/40 ,  C07D487/04 ,  C07D495/04 ,  C07D513/04 ,  C07F7/081 ,  C07F7/0812

摘要： The invention relates to the inhibition of histone deacetylase. The invention provides compounds and methods for inhibiting histone deacetylase enzymatic activity. The invention also provides compositions and methods for treating cell proliferative diseases and conditions.

摘要翻译： 本发明涉及抑制组蛋白脱乙酰酶。 本发明提供了抑制组蛋白脱乙酰酶酶活性的化合物和方法。 本发明还提供了治疗细胞增殖性疾病和病症的组合物和方法。

公开(公告)号：US06939986B2

公开(公告)日：2005-09-06

申请号：US10081345

申请日：2002-02-22

申请人： Martin Karpf ,  René Trussardi

发明人： Martin Karpf ,  René Trussardi

IPC分类号： B01J31/12 ,  C07B61/00 ,  C07C209/14 ,  C07C209/16 ,  C07C209/52 ,  C07C211/25 ,  C07C211/36 ,  C07C211/40 ,  C07C213/04 ,  C07C213/08 ,  C07C215/20 ,  C07C217/52 ,  C07C231/12 ,  C07C233/03 ,  C07C233/41 ,  C07C233/52 ,  C07C309/66 ,  C07C317/48 ,  C07C317/50 ,  C07C227/08 ,  C07C247/14 ,  C07D317/44

CPC分类号： C07C213/04 ,  C07C209/14 ,  C07C209/16 ,  C07C213/08 ,  C07C217/52 ,  C07C233/52 ,  C07C317/48 ,  C07C317/50 ,  C07C2601/16

摘要： The invention provides a multistep process for preparing 1,2-diamino compounds and pharmaceutically acceptable addition salts thereof from 1,2-epoxides.

摘要翻译： 本发明提供了从1,2-环氧化物制备1,2-二氨基化合物及其药学上可接受的加成盐的多步法。